# AS01B adjuvant mechanisms and CD4 T cell responses

## AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

## Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria.

## Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine.

## Screening

We screened in sources based on their abstracts that met these criteria:

- **AS01B Adjuvant Focus**: Investigates AS01B adjuvant specifically.
- **CD4 T Cell Response Measurement**: Measures CD4 T cell responses as primary or secondary outcomes.
- **Appropriate Study Type**: Human clinical trial or animal study using established laboratory models.
- **AS01B Data Availability**: Includes AS01B data.
- **CD4 T Cell Data Inclusion**: Includes CD4 T cell data.
- **CD4 T Cell Response Focus**: Includes CD4 T cell response data.
- **AS01B Effect Attribution**: Attributes effects specifically to AS01B.
- **Full Publication Status**: Full-text publication.

## Data extraction

We asked a large language model to extract each data column from each paper.
- **Study Context**: Key study design information relevant to AS01B mechanisms and CD4 T cell responses.
- **AS01B Mechanisms**: Mechanistic data showing how AS01B works at the innate immunity level.
- **CD4 Responses**: CD4 T cell response data specifically for AS01B.
- **Mechanism-Response Links**: Evidence directly connecting AS01B mechanisms to CD4 T cell responses.
- **Adjuvant Comparisons**: Comparative data between AS01B and other adjuvants.
- **Key Findings**: Main conclusions about AS01B adjuvant mechanisms and CD4 T cell responses.

## Results

### Characteristics of included studies

| Study |  Full text retrieved? | Study population | Antigen used with AS01B | Study design | Adjuvants compared | Sample size (AS01B group) |
|-------|------------------|------------------|--------------------------|---------------|--------------------|---------------------------|
| K. Kester et al., 2009 | No | Healthy human adults | RTS,S antigen | Double-blind, randomized trial | AS01B, AS02A | ~51 participants |
| M. Fochesato et al., 2016 | Yes | C57BL6 mice | VZV glycoprotein E (gE) | Comparative immunogenicity study | AS01B, AS01E, AS03, AS04 | Not mentioned |
| ... | ... | ... | ... | ... | ... | ... |

The included studies span multiple vaccine platforms and species, with three studies using full-text data and seven relying on abstract-only information. Studies evaluated AS01B across diverse antigens including malaria, herpes zoster, hepatitis B, and HIV-1. Study populations included healthy human adults, mice, and rhesus monkeys.

## AS01B mechanisms at the innate immunity level

| Study | Cytokines induced | Signaling pathways | Timeline of responses | Gene expression changes |
|-------|------------------|-------------------|----------------------|-----------------------|
| K. Kester et al., 2009 | IL-2, IFN-γ, TNF-α | Not mentioned | Not mentioned | Not mentioned |
| ... | ... | ... | ... | ... |

AS01B consistently induced IFN-γ production across multiple studies, demonstrating that AS01B induced transient innate responses including IL-6 and CRP, with increased IFN-γ levels after the second injection.

## CD4 T cell responses induced by AS01B

| Study | CD4 T cell markers/frequencies | Cytokine production | Functional assays | Persistence/durability | CD4 subset analysis |
|-------|-----------------------------|--------------------|-------------------|-----------------------|---------------------|
| K. Kester et al., 2009 | Median 963 vs 308 CSP-specific CD4+ T cells | Higher ex vivo IFN-γ ELISPOTs | IFN-γ ELISPOTs | Implied by rechallenge data | Not mentioned |
| ... | ... | ... | ... | ... | ... |

AS01B consistently induced robust CD4 T cell responses across diverse antigens and species.

## Comparative adjuvant effects

| Adjuvant | CD4 T cell response magnitude | Mechanistic profile | Key distinguishing features |
|----------|-----------------------------|---------------------|-----------------------|
| AS01B | Baseline | IFN-signaling pathway activation, IL-6, IFN-γ, CRP | Strongest CD4 responses, highest IFN-γ production |
| AS01E | Similar to AS01B | Comparable innate profiles | 50% less MPL and QS-21 | 
| ... | ... | ... | ... |

AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants.

## Mechanistic links between AS01B activation and CD4 T cell responses

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses, which underscores the significance of the differential pathway activation in enhancing vaccine immunogenicity.